Updates in HER2+ Early and Metastatic Breast Cancer : Episode 9

Data Updates in Adjuvant HER2+ Early Breast Cancer from SABCS 2022

Feb 21, 2023

Joyce O’Shaughnessy, MD
Virginia Borges, MD

The panel highlights recent data updates in adjuvant treatment of HER2+ early breast cancer, including longer-term follow-up data from the APT and ATEMPT trials.

EP: 1.Incidence and Typical Prognosis of HER2+ Early Breast Cancer

EP: 2.Neoadjuvant Treatment of HER2+ Early Breast Cancer

EP: 3.De-Escalation Approaches in Patients with HER2+ Early Breast Cancer

EP: 4.Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast Cancer

EP: 5.Factors Informing Adjuvant Treatment Selection in HER2+ Early Breast Cancer

EP: 6.Expert Perspectives on Clinical Experience with Ado-Trastuzumab Emtansine (T-DM1)

EP: 7.Clinical Data Updates on Adjuvant Pertuzumab/Trastuzumab for HER2+ Early Breast Cancer

EP: 8.Extended Adjuvant Neratinib Therapy for Patients with HER2+ Early Breast Cancer

EP: 9.Data Updates in Adjuvant HER2+ Early Breast Cancer from SABCS 2022

EP: 10.HER2+ mBC: First-Line Treatment Regimens

EP: 11.Second-Line Treatment of HER2+ mBC and Recent Data Updates

EP: 12.Options for Third- and Further-Line Treatment of HER2+ mBC

EP: 13.Use of MRI for Surveillance of Brain Metastases in Patients with HER2+ mBC

EP: 14.Emerging Data and Investigational Agents in HER2+ mBC

EP: 15.Unmet Needs and the Future of HER2+ Breast Cancer Treatment

Related Videos

Expert on breast cancer

Experts on DTC

Expert on breast cancer

Colin E. Champ, MD

Experts on lung cancer

Yuan Yuan, MD, PhD

Christie J. Hilton, DO

Experts on DTC

Expert on breast cancer

Related Content

Sacituzumab Govitecan Displays OS Benefit in Pretreated HR+/HER2– Breast Cancer

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

Zotatifin Triplet Shows Promising Activity, Low Toxicity in Heavily Pretreated ER+ Breast Cancer

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

Efficacy and Safety of Abemaciclib Plus ET Is Maintained Older Patients with HR+, HER2–, Early Breast Cancer

Addition of Ribociclib to Endocrine Therapy Provides iDFS Benefit in HR+/HER2– Early Breast Cancer

Sacituzumab Govitecan Displays OS Benefit in Pretreated HR+/HER2– Breast Cancer

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

Zotatifin Triplet Shows Promising Activity, Low Toxicity in Heavily Pretreated ER+ Breast Cancer

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

Efficacy and Safety of Abemaciclib Plus ET Is Maintained Older Patients with HR+, HER2–, Early Breast Cancer

Addition of Ribociclib to Endocrine Therapy Provides iDFS Benefit in HR+/HER2– Early Breast Cancer

Sacituzumab Govitecan Displays OS Benefit in Pretreated HR+/HER2– Breast Cancer

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

Zotatifin Triplet Shows Promising Activity, Low Toxicity in Heavily Pretreated ER+ Breast Cancer

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

Efficacy and Safety of Abemaciclib Plus ET Is Maintained Older Patients with HR+, HER2–, Early Breast Cancer

Addition of Ribociclib to Endocrine Therapy Provides iDFS Benefit in HR+/HER2– Early Breast Cancer

Related Content

Sara M. Tolaney, MD, MPH

Sacituzumab Govitecan Displays OS Benefit in Pretreated HR+/HER2– Breast Cancer

Francois-Clement Bidard, MD, PhD

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

Ezra Rosen, MD, PhD

Zotatifin Triplet Shows Promising Activity, Low Toxicity in Heavily Pretreated ER+ Breast Cancer

Patrick I. Borgen, MD; Laura J. Esserman, MD, MBA; Kelly K. Hunt, MD, FACS, FSSO; Kevin Kalinsky, MD, MS; Lisa A. Carey MD, ScM, FASCO, Steven J. Chmura, MD, PhD

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

A clinically meaningful absolute risk reduction in invasive disease-free survival and distant relapse-free survival with abemaciclib plus endocrine therapy was maintained in patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer regardless of age.

Efficacy and Safety of Abemaciclib Plus ET Is Maintained Older Patients with HR+, HER2–, Early Breast Cancer

Dennis J. Slamon, MD

Addition of Ribociclib to Endocrine Therapy Provides iDFS Benefit in HR+/HER2– Early Breast Cancer

Latest Conference Coverage

Extended Lymphadenectomy Does Not Lead to Survival Benefit in MIBC

Fianlimab/Cemiplimab Demonstrates Early Clinical Activity and Safety in Advanced Melanoma

in Genitourinary, Gastrointestinal, and Breast Cancers, Plus Sarcoma and Melanoma at ASCO 2023: Drs Rini, Lewis, Trent, Luke, Kunz, and Lustberg

ZUMA-7 Primary OS Analysis Supports Use of Axi-cel As Second-line SOC in R/R LBCL

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.